At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Gemcitabine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Oxaliplatin, and 1 other intervention for Mixed Mullerian Tumors of the Uterus. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
The purpose of this research study is to determine the feasibility and safety of giving the combination of oxaliplatin and gemcitabine followed by radiation therapy and to learn whether or not this drug combined with radiation therapy works in treating women with Mullerian tumors of the uterus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMixed Mullerian Tumors of the Uterus
CountriesUnited States
CollaboratorsSanofi, Brigham and Women's Hospital, Massachusetts General Hospital
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedMay 2007
Primary CompletionMar 2012
Study CompletionDec 2015
TodayJul 2026
First PostedMay 21, 2007
Enrollment StartAug 1, 2006
Primary CompletionMar 1, 2012
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 19.1 years ago
Interventions
Gemcitabinedrug
Oxaliplatindrug
Radiationradiation